Case Report

Unilateral Ocular Myasthenia Gravis


*Associate professor, **PG Student, ***HOD & Professor, Department of Ophthalmology, Chettinad Hospital & Research Institute.

Dr. Siddharam Janti did his graduation from Shri B.M. Patil Medical College and his post-graduation (M.S.Ophthalmology) from Madras Medical College, RIOGH. Further he did Fellowship in Medical Retina and Phacoemulsification from Dr. M.N. Eye Hospital. He completed DNB Ophthalmology from the National board of examination. His areas of interest include Retina and Neuro-ophthalmology. Currently he is working as an Associate Professor at the Department of Ophthalmology, Chettinad Hospital and Research Institute.

Corresponding author - Dr. Siddharam Janti (drsidharam@gmail.com)


Abstract

Myasthenia gravis, an acquired auto immune disease of the neuromuscular junction, has ophthalmic manifestations as integral part. Herewith we report a rare unicocular involvement of the eye in a 38yrs old male. He presented with the drooping of right upper eye lid since two years, worsening by evening and after exertion. Though the blood investigations and Ach antibody titres were normal, he responded well to 1.5mg neostigmine intramuscularly.

Key Words: Ocular myasthenia gravis, Neostigmine

Introduction

Myasthenia gravis (MG) is an acquired auto-immune disease of the neuromuscular junction which causes rapid muscle fatigue and weakness. Ocular manifestations are an integral part of Myasthenia gravis. Ptosis and diplopia are the initial complaint in around 75% to 90% cases. Ocular MG, in which weakness remains confined to the ocular muscles only, is encountered in up to 17% to 58% of all myasthenics. Some less common or rare ocular signs like paradoxical reversal of ptosis, enhanced ptosis, total external ophthalmoplegia, internuclear ophthalmoplegia, chronic progressive external ophthalmoplegia and lid retraction contralateral to the ptotic eye. Although bilateral ophthalmological involvement of disease is quite common, it is rare to find a case of unilateral Ocular Myasthenia Gravis.

Case Report

A 38 year old male presented to Ophthalmology OPD, Chettinad Health and Research Institute with a chief complaint of drooping of right upper eyelid since two years which was worsened by evening and on excessive work. He has no other systemic illness and no ocular complaints of diplopia.

On examination, visual acuity was 6/6 and extraocular movements were full. Right eye revealed ptosis was of 4mm, Bell’s phenomenon was normal, Levator palpebral action 7mm by Berke’s method with rest of the anterior segment and posterior segment being normal. Anterior and posterior segments were found to be in normal limits in left eye except mild lid retraction. Ice pack test was positive. The routine blood investigations were found to be in normal limits except the mild elevation of ESR levels. USG abdomen and HRCT chest were found to be in normal limits. The acetyl choline receptor antibody titres were found to be in normal titres. The patient was subjected to neostigmine test after obtaining anaesthetic fitness and with cardiac monitoring. After injection neostigmine 1.5 mg intramuscularly, the ptosis showed significant improvement after 30 minutes, confirming the diagnosis of Unilateral Ocular Myasthenia gravis. Neurologist opinion was obtained and advised tablet Pyridostigmine 60 mg thrice daily 8.

Discussion

Myasthenia gravis is a disease characterized by fatigue and weakness of the striated muscle within the body. Although the exact cause is unknown it is thought to be an acquired autoimmune disorder the defect lies at the postsynaptic membrane. 70 percent of patients with myasthenia gravis have visual symptoms in the initial presentation. Generally the female: male ratio in generalized myasthenia is 3:2 or higher. But on the contrary, ocular myasthenia is more in especially after the age of 40 years. In addition, the average age of onset for generalized myasthenia is 33 years, while that of ocular myasthenia is 38 years. 2 Common clinical features seen in patients with ocular MG are ptosis (droopy eyelids), diplopia (double vision) and incomplete eye closure. Environmental, emotional, and physical factors also found to influence the symptoms for the patients. The major factors found to affect them are bright sunlight, extreme temperature, emotional stress, illness, surgery, menstruation, and pregnancy. Symptoms were found to be worse at the end of the day during the evenings or after exertion of the muscle.

<table>
<thead>
<tr>
<th>Diagnostic Criteria For Ocular Myasthenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
</tbody>
</table>
Case Report
Unilateral Ocular Myasthenia Gravis

Elevated Ach receptor antibody confirms the diagnosis of Myasthenia gravis in 80% to 90% cases of Myasthenia gravis and 30-77% cases of Ocular myasthenia gravis. Of these patients, 30% will have autoantibodies against muscle specific kinase (anti MuSKAb) expressed on skeletal muscle. Patients who are negative for both Ach and MuSK antibodies are classified as “seronegative” Myasthenia gravis. CT scan should be done to rule out thymic hyperplasia. Thyroid function tests should be done to rule out autoimmune thyroid disease.2

Treatment is chiefly medical and aims at improving muscle weakness (thereby alleviating symptoms of diplopia and ptosis), achieving disease remission, minimizing drug induced side effects, and slowing or preventing progression to generalized Myasthenia.2 Medications include cholinesterase inhibitors such as Mestinon, pyridostigmine, steroids such as Prednisone, or other immunosuppressants used alone or in combination. Other options include plasmapheresis, or IV Ig therapy. These treatments offer only a temporary improvement and repeated treatments are necessary to sustain the effect. Supportive measures include the use of prisms or occlusion therapy for those with persistent diplopia and crutch glasses for severe ptosis2.

Conclusion
Eventhough Myasthenia gravis is a common neuromuscular junction disorder. Ocular myasthenia in the early stages is often misdiagnosed. So clinicians should examine each case with a high degree of suspicion. The diagnosis can be made with simple clinical and pharmacological tests.

References
2) Myasthenia Gravis Association of Western Pennsylvania. 2009: Medical advisory Board
8) Ocular Myasthenia Analysis of Diagnostic and Treatment Options Austin Hake and Henry J. Kaminski Department of Neurology & Psychiatry, Saint Louis University, St. Louis, MO USA